Report #2824543

Received Feb 4, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: 77 yrs
State: OH
Recovered: Unknown
Vaccinated: —
Onset: Jan 13, 2025
Days to onset: —
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
RSV	RSV (AREXVY)	GLAXOSMITHKLINE BIOLOGICALS	2	—	IM

Symptoms (1)

Extra dose administered

Symptom narrative

patient received second dose of Arexvy; This non-serious case was reported by a consumer via call center representative and described the occurrence of extra dose administered in a 77-year-old female patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis. Previously administered products included Arexvy (Patient received first dose one year ago). On 13-JAN-2025, the patient received the 2nd dose of Arexvy (intramuscular, right deltoid). On 13-JAN-2025, an unknown time after receiving Arexvy, the patient experienced extra dose administered (Verbatim: patient received second dose of Arexvy). The outcome of the extra dose administered was unknown. Additional Information: GSK Receipt Date: 14-JAN-2025 The patient reported that she received Arexvy vaccine twice, which led to extra dose administered.